Axi-cel in refractory large B-cell lymphoma, effects of C1 inhibitor deficiency on coagulation, and the evolution of therapy-related myeloid neoplasms
Blood Podcast
00:00
The Curative Potential of Axocel in Patients With Refractory B-Cell Lymphoma
Treatment with Axocel in the Zuma Wan trial resulted in an 83% objective response rate and a 58% complete response rate. At 5 years, estimated OS was 43% among all treated patients and 64% among those achieving a CR. No new adverse events or deaths attributable to Axocel were observed during the 5-year follow-up.
Transcript
Play full episode
